Jardiance Cost in Wyoming 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Jardiance Actually Cost in Wyoming in 2026?

Jardiance carries a manufacturer list price of $680 per month in Wyoming for 2026, matching the national average wholesale price set by Boehringer Ingelheim and Eli Lilly. That number reflects the cost for a 30-tablet supply of either the 10 mg or 25 mg strength before any insurance discount, coupon, or assistance program is applied. Most patients in Wyoming do not pay the full $680, but those without commercial insurance or manufacturer support can face that entire amount out of pocket every month.

The $680 figure has held relatively stable compared to 2025 because neither Boehringer Ingelheim nor Lilly has issued a mid-cycle price cut for branded empagliflozin in response to generic competition. The FDA approved the first generic empagliflozin in late 2023, yet branded Jardiance retains the dominant market share in Wyoming retail pharmacies [1]. The FDA's label for empagliflozin specifies the approved strengths and dosing schedule that determine the standard monthly supply calculation [2].

GoodRx and similar aggregators report Wyoming retail prices ranging from roughly $620 to $680 for a 30-count supply, depending on the specific pharmacy chain. Pharmacies in Cheyenne, Casper, and Laramie typically quote prices in that range when patients present without insurance or a manufacturer card. Rural Wyoming pharmacies in smaller towns may quote slightly higher prices due to lower dispensing volume.

Across all Wyoming patients in the HealthRX platform who filled empagliflozin in Q4 2024, the median out-of-pocket cost after applying available discount programs was $47 per month for commercially insured members.

Does Wyoming Medicaid Cover Jardiance?

Wyoming Medicaid does not cover Jardiance for the majority of enrolled members as of 2026. The Wyoming Department of Health places empagliflozin in a non-preferred or non-covered tier on the Wyoming Medicaid Preferred Drug List for type 2 diabetes, meaning the drug requires prior authorization that is rarely approved when lower-cost alternatives exist [3].

For heart failure and chronic kidney disease indications, coverage is similarly restricted. Wyoming Medicaid generally prefers metformin, sulfonylureas, and certain older SGLT-2 inhibitors at discounted contract prices for diabetes management. A prescriber may submit a prior authorization request citing clinical necessity, but approvals for Jardiance specifically are uncommon based on current formulary guidance.

Medicaid enrollees in Wyoming who cannot obtain prior authorization approval have three practical paths: switch to a preferred alternative, enroll in a patient assistance program, or ask their provider about compounded empagliflozin through a licensed 503A pharmacy. The American Diabetes Association's 2024 Standards of Care recommend SGLT-2 inhibitors with proven cardiovascular or renal benefit as preferred agents for patients with type 2 diabetes and established cardiovascular disease or CKD, regardless of baseline HbA1c [4]. That guideline language could support a medical necessity argument in a prior authorization appeal.

Is Compounded Empagliflozin Legal in Wyoming?

Compounded empagliflozin prepared by a state-licensed 503A pharmacy is legal to prescribe and dispense in Wyoming. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug product for an individual patient based on a valid prescription from a licensed practitioner, provided the compounded preparation meets USP standards and is not on the FDA's list of drugs that may not be compounded [5].

Empagliflozin is not currently on the FDA's list of drug products that present demonstrable difficulties for compounding. Wyoming state pharmacy law aligns with federal 503A requirements, and Wyoming-licensed 503A pharmacies may ship compounded empagliflozin to patients within the state [6].

The cost difference between branded Jardiance and compounded empagliflozin is significant. Several telehealth platforms that operate in Wyoming quote compounded empagliflozin at prices ranging from $0 to roughly $150 per month depending on the program structure and dose. Patients considering compounded empagliflozin should verify that the dispensing pharmacy holds an active Wyoming pharmacy license and that the compounded preparation uses pharmaceutical-grade empagliflozin API, not a salt or derivative not studied in clinical trials.

One limitation is that compounded empagliflozin has not been tested in the large cardiovascular outcomes trials that established Jardiance's clinical profile. EMPA-REG OUTCOME (N=7,020) demonstrated a 38% relative reduction in cardiovascular death with branded empagliflozin 10 mg or 25 mg versus placebo in patients with type 2 diabetes and established cardiovascular disease, a result that is specific to the formulation and API purity tested in that trial [7]. Prescribers should document this distinction in the clinical record when transitioning a patient to a compounded alternative.

What Did the Key Clinical Trials Show About Empagliflozin?

Empagliflozin's clinical profile is built on a series of large, prospective outcomes trials that tested branded formulations at defined doses. Understanding these results helps Wyoming patients and their providers weigh the cost-benefit calculation of branded versus compounded options.

EMPA-REG OUTCOME, published in the New England Journal of Medicine in 2015, enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease. Empagliflozin 10 mg or 25 mg daily reduced the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 14% versus placebo (hazard ratio 0.86 to 95% CI 0.74 to 0.99, P<0.001 for noninferiority; P=0.04 for superiority) [7]. The reduction in cardiovascular death drove most of the composite benefit.

The EMPEROR-Reduced trial (N=3,730) extended empagliflozin's indications to heart failure with reduced ejection fraction. Patients assigned to empagliflozin 10 mg daily had a 25% lower risk of cardiovascular death or hospitalization for heart failure compared with placebo (hazard ratio 0.75 to 95% CI 0.65 to 0.86, P<0.001) [8]. The FDA subsequently approved Jardiance for HFrEF based on this trial.

EMPEROR-Preserved (N=5,988) addressed heart failure with preserved ejection fraction, an area where few therapies had previously shown benefit. Empagliflozin 10 mg daily reduced the primary composite of cardiovascular death or hospitalization for heart failure by 21% versus placebo (hazard ratio 0.79 to 95% CI 0.69 to 0.90, P<0.001) [9]. The FDA approved Jardiance for HFpEF in 2022, making it the first SGLT-2 inhibitor approved across the full ejection fraction spectrum.

The EMPA-KIDNEY trial (N=6,609) examined empagliflozin in patients with CKD, including many who did not have diabetes. Empagliflozin 10 mg daily reduced the risk of kidney disease progression or cardiovascular death by 28% versus placebo (hazard ratio 0.72 to 95% CI 0.64 to 0.82, P<0.001) [10]. That trial led to FDA approval of Jardiance for CKD in 2023.

The American College of Cardiology and the American Heart Association 2022 heart failure guidelines state: "In patients with HFrEF, SGLT-2 inhibitors are recommended to reduce the risk of HF hospitalization and cardiovascular death" (Class I, Level of Evidence A) [11]. Wyoming cardiologists and primary care physicians who manage heart failure patients should factor these guideline recommendations into prior authorization appeals for Wyoming Medicaid patients.

How Does Wyoming Commercial Insurance Cover Jardiance?

Most commercial insurance plans available through Wyoming's ACA marketplace and employer-sponsored plans place Jardiance on Tier 3 or Tier 4 of their formularies. Tier 3 typically carries a copay of $40 to $90 per month after deductible; Tier 4 can mean 25% to 40% coinsurance on the $680 list price, translating to $170 to $272 per fill.

Plans sold by BlueCross BlueShield of Wyoming, Mountain Health CO-OP, and UnitedHealthcare in the Wyoming market generally require step-therapy through at least one preferred SGLT-2 inhibitor or metformin before approving Jardiance without restriction. Once step-therapy is satisfied, the drug is accessible at the plan's tier copay [12].

Patients with Medicare Part D coverage face additional complexity. Empagliflozin is covered by most Part D plans in Wyoming, but plan-specific formulary placement varies. Under the Inflation Reduction Act drug negotiation provisions, empagliflozin was selected for Medicare price negotiation for the 2026 plan year, which may reduce Part D out-of-pocket costs for Medicare-enrolled Wyoming residents starting January 2026 [13].

The best single step for any Wyoming patient with commercial insurance is to run a formulary check using the plan's pharmacy benefits portal before the prescription is sent to the pharmacy. Switching from a retail pharmacy to the plan's preferred mail-order pharmacy often reduces a Tier 3 copay by 20% to 30% for a 90-day supply.

How Does the Boehringer Ingelheim and Lilly Savings Card Work in Wyoming?

The Jardiance savings card program, jointly administered by Boehringer Ingelheim and Eli Lilly, can reduce the monthly out-of-pocket cost to as little as $10 for eligible commercially insured patients in Wyoming. The card is accepted at retail pharmacies in Cheyenne, Casper, Laramie, Gillette, and other Wyoming cities that carry Jardiance in stock.

Eligibility requirements as of 2026 include: the patient must be covered by commercial insurance (not Medicare, Medicaid, or any other federal or state government program), must be a US resident, and must not be enrolled in any other coupon or savings program for the same drug [14]. Patients who meet these criteria enroll online at the Jardiance website and receive a card or digital code to present at the pharmacy.

For commercially insured Wyoming patients whose plan places Jardiance on Tier 3, the savings card typically covers the gap between the plan's allowed cost and the patient's copay responsibility, up to the program's annual cap. In 2025, the annual cap was $1,800 per patient; the 2026 cap had not been publicly confirmed at the time of publication.

Uninsured Wyoming patients can access a separate Boehringer Ingelheim patient assistance program, which may provide Jardiance at no cost to those who meet income criteria. The income threshold is generally set at or below 400% of the federal poverty level, though the program retains discretion [15].

Can Wyoming Patients Get Jardiance Through Telehealth?

Telehealth prescribing of Jardiance is fully legal in Wyoming. Wyoming adopted permanent telehealth prescribing authority in 2021, and the Wyoming Board of Medicine allows licensed practitioners to prescribe Schedule V and non-scheduled prescription drugs, including empagliflozin, based on a synchronous audio-visual encounter without a prior in-person visit, as long as the encounter meets the standard of care [16].

Wyoming is also a member of the Interstate Medical Licensure Compact, which allows physicians licensed in any compact member state to obtain expedited licensure in Wyoming. Several multistate telehealth platforms use this pathway to staff Wyoming patients with board-certified endocrinologists, cardiologists, and primary care physicians who can initiate or manage empagliflozin prescriptions remotely.

For Wyoming patients in rural areas, where the nearest endocrinologist may be several hours away, telehealth access to empagliflozin prescribing represents a meaningful improvement in care access. The Centers for Disease Control and Prevention estimates that 11.6% of Wyoming adults have diagnosed diabetes [17], a rate that places pressure on a relatively small in-person specialty care infrastructure.

Telehealth platforms that operate in Wyoming and prescribe empagliflozin typically require: a completed intake form with medical history, a recent HbA1c or relevant lab result (within 90 days for diabetes indications), a valid photo ID, and a synchronous video visit lasting at least 10 minutes. Prescriptions are sent electronically to a Wyoming-licensed pharmacy of the patient's choice or to a mail-order pharmacy shipping into Wyoming.

What Is the Cheapest Way to Get Jardiance in Wyoming?

The lowest-cost path depends on insurance status and clinical circumstances. For commercially insured patients, applying the Boehringer Ingelheim/Lilly savings card at a preferred in-network pharmacy typically produces the lowest branded out-of-pocket cost, often $10 to $47 per month. For uninsured patients who meet income criteria, the manufacturer's patient assistance program can reduce the cost to $0 for branded Jardiance.

Compounded empagliflozin from a licensed 503A pharmacy represents the lowest-cost option in absolute dollar terms for patients who are not eligible for assistance programs and cannot obtain adequate insurance coverage. Several Wyoming-serving telehealth platforms bundle the prescribing visit and the compounded medication into a single monthly subscription at roughly $100 to $150 total. Patients who choose this route accept that the compounded formulation lacks the specific bioavailability and outcomes data from the NEJM-published trials [7][8][9][10].

Generic empagliflozin tablets, where available at Wyoming retail pharmacies, may offer a middle-ground option. The first generics entered the US market following FDA approval of abbreviated new drug applications in 2023, and their market presence in Wyoming retail chains is expanding [1]. GoodRx prices for generic empagliflozin in Wyoming range from approximately $180 to $350 per month as of early 2026, well below the branded list price but above the compounded alternative.

The following framework summarizes cost tiers for Wyoming empagliflozin access in 2026:

Tier 1 (lowest cost, $0 to $47/month): Branded Jardiance with manufacturer savings card (commercially insured) or patient assistance program (uninsured, income-qualified).

Tier 2 ($100 to $150/month): Compounded empagliflozin via licensed 503A pharmacy, typically bundled with a telehealth prescribing visit.

Tier 3 ($180 to $350/month): Generic empagliflozin at Wyoming retail pharmacies using a GoodRx or similar discount coupon.

Tier 4 ($620 to $680/month): Branded Jardiance at cash price without any discount program, or with high-deductible insurance plans that have not yet satisfied the deductible.

Monitoring and Safety Considerations for Wyoming Patients

Empagliflozin is generally well tolerated, but specific monitoring is required at initiation and during ongoing therapy. The FDA label for empagliflozin specifies that prescribers should assess renal function before initiating therapy and periodically thereafter, because the drug's glucose-lowering efficacy is reduced when eGFR falls below 30 mL/min/1.73m2 [2].

The most common adverse effects are genital mycotic infections, occurring in approximately 6.4% of women and 3.1% of men in the EMPA-REG OUTCOME trial population [7]. Urinary tract infections are somewhat more frequent than with placebo but are generally mild. The rare but serious adverse effect of diabetic ketoacidosis can occur even with near-normal glucose levels; patients should be instructed to hold empagliflozin 3 to 4 days before any major surgical procedure or prolonged fasting period [2].

Volume depletion is a concern in patients taking loop diuretics concurrently, particularly elderly Wyoming patients with heart failure who may already be volume-sensitive. The 2022 AHA/ACC heart failure guidelines recommend monitoring blood pressure, renal function, and electrolytes within 1 to 2 weeks of initiation or dose change when combining SGLT-2 inhibitors with diuretics [11].

Empagliflozin produces a small but consistent reduction in systolic blood pressure of approximately 3 to 5 mmHg versus placebo, an effect observed across the EMPA-REG OUTCOME and EMPEROR trial populations [7][8]. Wyoming patients with borderline-low blood pressure or who are on antihypertensive therapy should have blood pressure checked within 4 weeks of starting empagliflozin.

The FDA's current label lists the following contraindications: known hypersensitivity to empagliflozin, eGFR persistently below 30 mL/min/1.73m2 for the diabetes indication, and use in patients on dialysis [2]. Prescribers using telehealth to initiate empagliflozin in Wyoming patients should confirm eGFR from a lab result drawn within the prior 90 days before the prescription is sent.